Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars H Lindner

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
Cancer Medicine|February 26, 2025
Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score-Matched AnalysisLuc M Berclaz, Vindi Jurinovic, Anton Burkhard-Meier, et al.
Cancer Research|September 7, 2012
Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumorsAshley A Manzoor, Lars H Lindner, Chelsea D Landon, et al.
Clinical & Experimental Metastasis|February 29, 2024
Differentiation of benign and metastatic lymph nodes in soft tissue sarcomaAnton Burkhard-Meier, Vindi Jurinovic, Luc M Berclaz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trialPatrick Schöffski, Agnieszka Wozniak, Bernard Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2020
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup StudyViktor Grünwald, Annika Karch, Markus Schuler, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|July 19, 2023
Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic reviewParaskevi Danai Veltsista, Eva Oberacker, Adela Ademaj, et al.
International Journal of Cancer|February 1, 2018
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Lars H Lindner, Saskia Litière, Stefan Sleijfer, et al.
Journal of Cancer Research and Clinical Oncology|April 26, 2025
First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysisAnton Burkhard-Meier, Vera Valerie Rechenauer, Vindi Jurinovic, et al.
Acta Oncologica (Stockholm, Sweden)|January 15, 2025
Maintenance treatment with trofosfamide in patients with advanced soft tissue sarcoma - a retrospective single-centre analysisAnton Burkhard-Meier, Vera Valerie Rechenauer, Luc M Berclaz, et al.
JAMA Oncology|May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-upHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
Cancer Medicine|February 26, 2025
Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score-Matched AnalysisLuc M Berclaz, Vindi Jurinovic, Anton Burkhard-Meier, et al.
Cancer Research|September 7, 2012
Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumorsAshley A Manzoor, Lars H Lindner, Chelsea D Landon, et al.
Clinical & Experimental Metastasis|February 29, 2024
Differentiation of benign and metastatic lymph nodes in soft tissue sarcomaAnton Burkhard-Meier, Vindi Jurinovic, Luc M Berclaz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trialPatrick Schöffski, Agnieszka Wozniak, Bernard Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2020
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup StudyViktor Grünwald, Annika Karch, Markus Schuler, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|July 19, 2023
Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic reviewParaskevi Danai Veltsista, Eva Oberacker, Adela Ademaj, et al.
International Journal of Cancer|February 1, 2018
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Lars H Lindner, Saskia Litière, Stefan Sleijfer, et al.
Journal of Cancer Research and Clinical Oncology|April 26, 2025
First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysisAnton Burkhard-Meier, Vera Valerie Rechenauer, Vindi Jurinovic, et al.
Acta Oncologica (Stockholm, Sweden)|January 15, 2025
Maintenance treatment with trofosfamide in patients with advanced soft tissue sarcoma - a retrospective single-centre analysisAnton Burkhard-Meier, Vera Valerie Rechenauer, Luc M Berclaz, et al.
JAMA Oncology|May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-upHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Pageof 14